Reata Pharmaceuticals has been acquired by Biogen. Please visit www.biogen.com for more information.
We focus on areas of substantial unmet need
Reata’s lead candidate has been developed for the treatment of chronic and genetic diseases for which a substantial unmet need exists. Our pipeline of therapeutics is focused on neurology.